论文信息 - Results of a phase II trial of ramucirumab plus irinotecan as second-line treatment for patients with advanced gastric cancer (HGCSG 1603). - 字舞流文

Results of a phase II trial of ramucirumab plus irinotecan as second-line treatment for patients with advanced gastric cancer (HGCSG 1603).

Y. Sakata | N. Sakamoto | Y. Komatsu | Y. Tsuji | A. Sato | H. Okuda | S. Yuki | A. Ishiguro | Michio Nakamura | K. Harada | Y. Kawamoto | Y. Shindo | S. Nakano | S. Sogabe | M. Dazai | K. Sawada | O. Muto | H. Nakatsumi | M. Sekiguchi | T. Sasaki